Eagle Pharmaceutical (EGRX) 53.00 $EGRX SHAREHOLDER

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 9:19 AM

Eagle Pharmaceutical (EGRX) 53.00 $EGRX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
EGRX: 53.00 (+11.53)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 53.00 (+11.53)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Eagle Pharmaceuticals Inc. and Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Jun 08, 2:39PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"

(Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EGRX: 53.00 (+11.53)

EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors to Securities Class Action and August 1, 2016 Lead Plaintiff Deadline
GlobeNewswire - Tue Jun 07, 7:30AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 53.00 (+11.53)

INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm
BusinessWire - Mon Jun 06, 8:34PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company"

(Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EGRX: 53.00 (+11.53)

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
PR Newswire - Mon Jun 06, 6:15PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ: EGRX) common stock during the period between February 23, 2016 and March 18, 2016, inclusive (the "Class Period"

.
EGRX: 53.00 (+11.53)

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc.
BusinessWire - Mon Jun 06, 5:20PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period"

. The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws.
EGRX: 53.00 (+11.53)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 06, 2:22PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between February 23, 2016 through March 18, 2016.
EGRX: 53.00 (+11.53)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Eagle Pharmaceuticals, Inc. and Certain Officers - EGRX
GlobeNewswire - Fri Jun 03, 5:17PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ:EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
EGRX: 53.00 (+11.53)

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. (EGRX) and Encourages Investors to Contact the Firm
BusinessWire - Fri Jun 03, 3:00PM CDT
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who acquired Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between February 23, 2016 and March 18, 2016 (the "Class Period"

.
EGRX: 53.00 (+11.53)

Robbins Arroyo LLP: Eagle Pharmaceuticals, Inc. (EGRX) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Fri Jun 03, 1:39PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Eagle Pharmaceuticals, Inc. (NASDAQGM: EGRX) in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016, for alleged violations of the Securities Exchange Act of 1934 by Eagle Pharmaceuticals' officers and directors. Eagle Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.
EGRX: 53.00 (+11.53)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ortho Molecular and HANS: Streamlining Functional Medicine

Functional Medicine Gets a Tech Boost The world of functional medicine just got a major shot in the arm, courtesy of an intriguing alliance between Ortho Molecular Products and HANS.FM. First of all, let's address the elephant in the room: clinicians in this field aren't exactly on a coffee break. They’re buried under mountains of paperwork, often spending hours just...

CURE Intl and Thoughtworks Step Into Digital Era

Pushing Paper Out, Digitizing In In a world where tech is king, why were hospitals—crucial, life-saving institutions—still bogged down by dusty folders and ink smudges? Well, not anymore for CURE International, not with Thoughtworks stepping up to the plate. This ain't just swapping paper for pixels; it's a lifeline for kids getting world-class surgical care without...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Agilyx's Q3 Update: GreenDot Shines Amid Mixed Results

Peeking into Agilyx's Financial Odyssey Just as I sip my morning coffee pondering the highs and lows of the market, here comes Agilyx ASA splashing some liquidity on the scene. The Q3 report paints the company in various shades—from solid greens to hesitant reds. Nothing like the thrill of untangling mixed results over a quiet day, huh? GreenDot's Climb to Profitability...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

LG Innotek Scores Hat Trick with CES Innovation Wins

LG Innotek's Lighting Triumph Here we go again, LG Innotek just snagged their third CES Innovation Award in a row, this time for their cutting-edge vehicle lighting module, Nexlide C+. It's one for the books—breaking into the 2027 CES spotlight with innovative tech that not only grabs the eyes but could also steal the hearts of investors willing to bet on the future of...

RF MEDICAL Expands into Europe with New CE Certification

RF MEDICAL Secures CE Marking for Mi-BLATOR™ Just when you think the European medical device market's hit its saturation point, RF MEDICAL decides to kick the door open with their Mi-BLATOR™ microwave ablation system. This ain't just another plastic gadget, folks; it's got that shiny new CE marking under the European Union's Medical Device Regulation (MDR). Now, what...

BD Sets Stage for Investor Day in December 2026

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...